In the weeks and months before an IVF cycle, couples frequently ask a version of the same question: is there anything we can do to improve our chances? Is there something in how we are living — what we eat, how we exercise, what we avoid — that might make the difference?
The question is asked with genuine hope and genuine uncertainty. And it deserves a genuinely honest answer — not the enthusiastic endorsement of every lifestyle intervention that appears in fertility wellness content, and not the dismissive response that nothing outside of clinical protocol affects outcomes. Both of those extremes misrepresent the evidence.
The honest answer is nuanced. Some lifestyle factors have a documented, clinically meaningful association with IVF outcomes — and modifying them represents a genuine clinical opportunity. Others are surrounded by far more marketing enthusiasm than scientific evidence. And the distinction between these two categories matters enormously for couples who want to invest their energy in what actually helps — rather than in the elaborate preparatory rituals that the fertility wellness industry has constructed around IVF.
This article examines the evidence for each major lifestyle domain — smoking, alcohol, body weight, exercise, sleep, stress, and specific nutritional factors — and provides the honest clinical assessment of what the evidence supports, what it does not, and where the uncertainty lies.
Smoking — The Clearest Evidence, the Most Significant Impact
Of all lifestyle factors, smoking has the most consistent, most robust, and most clinically significant association with impaired IVF outcomes. The evidence is not equivocal. It is not modest. It is the strongest signal in the lifestyle and IVF literature.
In women: Smoking is associated with reduced ovarian reserve — AMH is lower in smokers than in non-smokers, even after adjusting for age — because the toxic compounds in cigarette smoke (particularly polycyclic aromatic hydrocarbons) accelerate follicle atresia in the primordial pool. Smokers produce fewer eggs per stimulation cycle, have lower fertilization rates, have higher embryo arrest rates, and have substantially lower live birth rates per IVF cycle than non-smokers of comparable age and reserve. Meta-analyses consistently find that smoking reduces IVF live birth rates by approximately thirty to forty percent compared to non-smokers.
In men: Smoking is one of the most important modifiable causes of elevated sperm DNA fragmentation. The oxidative stress generated by cigarette smoke causes direct DNA damage in developing spermatocytes and mature sperm. Men who smoke have consistently higher DFI than non-smokers — and elevated DFI, as established throughout this content library, impairs embryo developmental competence and implantation in ways that are invisible to standard semen analysis.
The timing of cessation: The benefit of smoking cessation on IVF outcomes is real but requires adequate lead time. Spermatogenesis — the full cycle of sperm production — takes approximately seventy to seventy-four days. A man who stops smoking today will begin to see improvement in sperm DNA fragmentation in approximately two to three months. Ovarian follicle development occurs over a shorter period — but the systemic effects of smoking on ovarian function may take months to partially reverse. The recommendation at Metro IVF is cessation at least three months before an IVF cycle — both partners.
The message is unequivocal: Smoking cessation is the single most impactful lifestyle intervention available to IVF patients. The evidence is robust, the mechanism is understood, and the clinical magnitude of the effect is large. For couples who smoke, this is not optional advice — it is a clinical priority.
Alcohol — Meaningful Association, Dose-Dependent Effect
The evidence for alcohol's effect on IVF outcomes is consistent across multiple studies — and the effect is dose-dependent, meaning that the impact increases with the amount consumed.
A large prospective cohort study of women undergoing IVF demonstrated that women who consumed four or more drinks per week had a significantly lower live birth rate than women who consumed fewer drinks or none — even after adjusting for age, BMI, and other confounders. A similar dose-dependent relationship has been found for male partners — men who consume four or more drinks per week have lower sperm parameters and higher DNA fragmentation than lighter drinkers or non-drinkers.
The mechanisms are plausible and documented. Alcohol is a direct testicular and ovarian toxin at significant doses — impairing Sertoli and Leydig cell function in men, disrupting FSH and LH secretion in women, and exerting direct toxic effects on developing gametes through reactive oxygen species and acetaldehyde.
The clinical recommendation: Abstinence or significant reduction during the IVF cycle itself — from the start of stimulation through the pregnancy test — is the recommendation at Metro IVF. In the two to three months of pre-cycle preparation, reduction to one to two drinks per week at most — and ideally complete abstinence — represents the most evidence-aligned approach.
The cultural reality in India — where alcohol consumption patterns differ significantly from Western contexts, and where the majority of female patients are non-drinkers — means that this recommendation is primarily relevant to male partners in many of the couples Metro IVF treats. For women who do drink, even light alcohol consumption in the peri-IVF period carries an evidence-based rationale for cessation.
Body Weight and BMI — A Meaningful Effect With Important Nuance
The relationship between body weight and IVF outcomes is one of the most studied in the lifestyle literature — and one of the most carefully nuanced when communicated to patients.
Obesity and IVF outcomes. Elevated BMI — particularly obesity (BMI above 30 in European references, BMI above 25 in Indian references where metabolic disease manifests at lower BMI) — is consistently associated with poorer IVF outcomes. Obese women have lower ovulation rates, produce fewer mature eggs per stimulation cycle, have lower fertilization rates, and have lower implantation rates than normal-weight women. The mechanisms involve insulin resistance — amplifying androgen excess and disrupting follicular development — and elevated adipose tissue-derived estrogen — altering the hormonal environment of the cycle.
In the IVF laboratory, embryos from obese women are more likely to show developmental arrest, lower blastocyst rates, and poorer morphology — suggesting that the impairment extends to the quality of the eggs themselves, not only to the hormonal stimulation environment.
The evidence for weight loss improving IVF outcomes. For obese women, weight loss before IVF consistently improves ovarian stimulation response, egg quality, and — in multiple studies — live birth rates per cycle. A weight loss of five to ten percent of body weight produces measurable hormonal improvements — reduced insulin resistance, reduced androgen levels, improved FSH sensitivity — within weeks to months. The clinical recommendation for significantly overweight or obese women at Metro IVF is to achieve meaningful weight reduction before the first IVF cycle, where the timeline allows it.
The underweight concern. Significantly underweight women — BMI below 18.5 — have impaired ovulatory function through hypothalamic suppression related to insufficient energy availability. This is particularly relevant in women with restrictive eating patterns or in those who have dramatically restricted dietary intake in preparation for IVF in the mistaken belief that weight loss will help. The goal is a healthy, nutritionally adequate body weight — not the lowest achievable weight.
The critical nuance about timing and urgency. For women with significantly diminished ovarian reserve — low AMH, very few antral follicles — the recommendation to delay IVF for weight loss must be carefully weighed against the cost of deferring treatment while the reserve continues to decline. A woman with an AMH of 0.4 ng/mL who is moderately overweight faces a different benefit-risk calculation from a woman with a normal AMH who is significantly obese. Weight management advice must be individualized to the specific clinical urgency of the case.
Exercise — Beneficial at Moderate Intensity, Potentially Harmful at High Intensity
The exercise evidence for IVF is more nuanced than for smoking, alcohol, or weight — and the direction of effect depends significantly on the intensity and duration of the exercise.
Moderate physical activity — beneficial. Regular moderate exercise — walking, swimming, cycling, yoga — is associated with improved IVF outcomes in multiple observational studies. The mechanisms are consistent with what is known about exercise physiology: moderate physical activity improves insulin sensitivity, reduces systemic inflammation, improves cardiovascular fitness, and reduces the stress hormones that can impair reproductive function. Women who engage in regular moderate physical activity before IVF have better ovarian reserve markers and better IVF outcomes than sedentary women.
High-intensity vigorous exercise — potentially harmful. Several studies have found that very high volumes of vigorous exercise — particularly running more than sixty minutes per day, or participation in competitive-level endurance sports — are associated with reduced IVF success rates. The proposed mechanisms include exercise-induced disruption of the hypothalamic-pituitary axis at extreme intensities, reduction of uterine blood flow, and the caloric deficit that may accompany very high training volumes.
During stimulation and around retrieval. Vigorous exercise is specifically discouraged during the stimulation phase of IVF — both because enlarged ovaries are vulnerable to torsion with high-impact activity, and because the physical demands of vigorous exercise compete with the metabolic demands of follicular development. Brisk walking and gentle yoga are appropriate. Running, high-impact exercise, and heavy lifting are not.
The clinical recommendation: Regular moderate exercise in the months before IVF — three to five sessions per week of thirty to forty-five minutes of moderate-intensity activity — is evidence-supported and clinically recommended. High-intensity competitive training should be moderated. All vigorous exercise should be suspended during the stimulation phase.
Sleep — Emerging Evidence, Plausible Mechanisms
Sleep is an emerging area of lifestyle research in reproductive medicine — less studied than smoking, alcohol, and weight, but with a growing evidence base supporting its clinical relevance.
The reproductive hormonal system is deeply tied to circadian biology — the body's internal clock that coordinates biological processes across the twenty-four-hour cycle. FSH, LH, prolactin, melatonin, and cortisol all show circadian patterns of secretion that are disrupted by sleep deprivation, shift work, and circadian misalignment.
Melatonin — the pineal hormone that signals darkness and coordinates circadian timing — has specific relevance to IVF. The follicular fluid within ovarian follicles contains melatonin at concentrations higher than in the blood, and melatonin functions as an antioxidant within the follicle — protecting the egg from oxidative damage during the intensive metabolic activity of follicle growth. Women with poor sleep quality and disrupted melatonin secretion have lower follicular melatonin concentrations and poorer egg quality in some studies.
Several studies have examined the association between sleep duration, sleep quality, and IVF outcomes — finding that women sleeping fewer than seven hours per night or more than nine hours per night have lower IVF success rates than those sleeping seven to eight hours. The optimal sleep duration for IVF is broadly consistent with the general health recommendation of seven to eight hours per night.
The clinical recommendation: Seven to eight hours of sleep per night during the weeks before and during an IVF cycle. Avoidance of night shift work, where possible, in the weeks surrounding the cycle. Melatonin supplementation — at low doses of one to three mg at bedtime — is considered by some fertility specialists for patients with documented poor sleep quality or circadian disruption, though the evidence for this specific supplementation is preliminary.
Stress — Real Effect, Complex Mechanisms, Manageable
The question of whether stress affects IVF outcomes is one of the most emotionally charged in fertility medicine — partly because it risks placing blame on patients for an outcome that is primarily biological, and partly because infertility itself is one of the most stressful experiences a couple can face.
The evidence is nuanced. Severe, chronic psychological stress — not the ordinary anxiety of going through IVF, but the elevated cortisol and sympathetic nervous system activation associated with significant untreated mental health disturbance — is associated with modestly reduced IVF success rates in some studies. The magnitude of the effect is not large — it does not approach the effect size of smoking, for example — and many large studies have not found a significant association.
What the evidence does consistently show is that psychological support during IVF — whether through structured psychological interventions, counseling, or peer support — reduces the psychological burden of the treatment and improves the couple's experience, regardless of whether it measurably improves the biological outcome. Given that IVF is one of the most emotionally demanding medical experiences that exists, psychological support has independent value that does not require a fertility outcome justification.
The clinical recommendation: Active psychological support — in whatever form is accessible and acceptable to the couple — during IVF. This may mean professional counseling, peer support groups, mindfulness-based stress reduction, or simply ensuring that the clinical team at Metro IVF provides the kind of attentive, communicative care that reduces the anxiety-amplifying effect of inadequate information and inadequate engagement.
What the evidence does not support: The recommendation to "just relax and it will happen" as a clinical intervention for infertility, or the attribution of IVF failure to the patient's stress level. These framings are not only clinically inaccurate — they are harmful, placing responsibility for a biological outcome on the patient's emotional state in a way that compounds the suffering of infertility rather than addressing it.
Nutritional Supplementation — Where the Evidence Is Strongest
Folic acid. The evidence for folate supplementation before and during pregnancy — primarily for the prevention of neural tube defects — is among the strongest in all of nutritional science. Four hundred to eight hundred micrograms of folic acid daily from pre-conception through the first trimester is universally recommended and universally appropriate for all women undergoing IVF.
Vitamin D. Vitamin D deficiency — extremely common in India across all regions and demographics — is consistently associated with poorer IVF outcomes in multiple studies. Vitamin D receptors are expressed in ovarian tissue, the endometrium, and in the immune cells that regulate implantation. Women with adequate vitamin D levels have better IVF outcomes than deficient women in most but not all studies. Correction of documented vitamin D deficiency before IVF — typically with 1000 to 2000 IU daily, or higher doses if deficiency is severe — is an inexpensive, safe, and evidence-supported intervention.
CoQ10. Coenzyme Q10 — which supports mitochondrial function in developing eggs — has a rational biological basis and a growing clinical evidence base in women over 35 and in women with diminished ovarian reserve. Doses of 400 to 600 mg daily of the ubiquinol form for two to three months before IVF are recommended at Metro IVF for appropriate patients. The evidence is not definitive — large randomised trials are limited — but the biological rationale is strong and the safety profile is excellent.
Omega-3 fatty acids. Omega-3 supplementation has been associated with improved egg quality and embryo quality in some studies, possibly through anti-inflammatory effects on the ovarian microenvironment. The evidence is preliminary — not yet at the level of strong clinical recommendation — but the safety profile is favorable and the dietary context in India, where omega-3 intake from fish is variable, makes supplementation reasonable for many patients.
What the evidence does not support: Elaborate proprietary "fertility supplement" packages, "detox" preparations, herbal supplements with unregulated content, and the many products marketed specifically to IVF patients with claims that outrun the evidence significantly. The supplement landscape for fertility is heavily commercialized, and the marketing enthusiasm for many products far exceeds the scientific evidence. At Metro IVF, supplementation recommendations are specific, evidence-based, and limited to what the research actually supports.
The Clinical Summary — What Actually Matters
The lifestyle interventions with the strongest evidence for improving IVF outcomes, in descending order of evidence strength, are:
Smoking cessation — for both partners, at least three months before the cycle. The evidence is strongest, the effect size is largest, and there is no upper limit to the benefit of cessation.
Alcohol reduction or cessation — both partners, during the cycle and ideally for two to three months before it.
Weight management — specifically, meaningful weight loss in significantly overweight or obese patients, individualized to the urgency of the clinical timeline.
Vitamin D correction — for documented deficiency, which is common across India.
Folic acid supplementation — for all women undergoing IVF.
CoQ10 supplementation — for women over 35 and women with diminished reserve.
Moderate regular exercise — three to five sessions weekly of moderate intensity, suspended during stimulation.
Adequate sleep — seven to eight hours nightly.
Psychological support — in whatever accessible form reduces the burden of the experience.
The lifestyle interventions without evidence support — the proprietary detox programmes, the elaborate dietary protocols, the herbal supplements, the "positive thinking" prescriptions — do not belong on this list. They consume the couple's energy, finances, and emotional resources without clinical return. Couples who pursue them instead of evidence-based interventions are not better prepared — they are equally unprepared but more depleted.
The evidence supports specific, targeted lifestyle optimization. That optimization, undertaken with the clinical guidance of a specialist who knows what the evidence actually shows, is a genuine and meaningful contribution to the best possible IVF outcome.
Your Next Step
If you want to understand which specific lifestyle modifications are most relevant to your individual situation — your specific risk factors, your clinical history, and the timeline of your IVF plan — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur provides the most complete and evidence-based guidance available.
The preparation you do before your IVF cycle matters. Doing the right preparation — specific to your situation, based on the actual evidence — is part of giving your cycle the best possible foundation.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
The right lifestyle preparation makes a real difference. Book your consultation with Dr. Ashish Soni at Metro IVF today.